# Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals

> **NCT01862029** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 24 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Roflumilast

## Key facts

- **NCT ID:** NCT01862029
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-22
- **Primary completion:** 2017-07-25
- **Final completion:** 2017-07-25
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01862029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01862029, "Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01862029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*